Program
HS-10541
A development code.
In Hansoh Pharmaceutical Group's pipeline, KRAS G12C
. Its studies are led by Hansoh Pharmaceutical Group.
Furthest: phase 1, since May 14, 20261 company-led study, 1 open or runningNext primary completion: Jun 30, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 11 open or running | phase 1since May 14, 2026 | May 14, 2026 | Jun 30, 2029phase 1 · NCT07615413 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-10541 (KRAS G12C)
, phase 1, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 14, 2026First study: phase 1 study in KRAS G12C Mutation Advanced Solid TumorFirst studyNCT07615413 · 636 planned
Ahead
- Jun 30, 2029Primary completion: phase 1 study in KRAS G12C Mutation Advanced Solid TumorNCT07615413
TargetBeta
“KRAS G12C”the company's pipeline, read by Claude · source
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07615413KRAS G12C Mutation Advanced Solid Tumor | 1 | Not yet recruiting | Jun 30, 2029 | 636 |
How it is read
Names in the registry
- “HS-10541”, 1 entry
Codes read as this program: HS10541.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.